# DoW Breast Cancer, Breakthrough Award Level 3

Source: https://welltoldgrants.com/grants/ht942526bcrpbta3-dow-breast-cancer-breakthrough-award-level-3/  
Official notice: https://www.grants.gov/search-results-detail/362203

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 2 awards worth $12.6 million in total. Applications closed on September 30, 2026.

| Field | Value |
|---|---|
| Opportunity number | HT942526BCRPBTA3 |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | September 30, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 2 |
| Total funding | $12.6 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3. Distinctive Features: · For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option. · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

## Questions people ask

### Is HT942526BCRPBTA3 still open?

No. It closed on September 30, 2026. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DoW Breast Cancer, Breakthrough Award Level 3?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DoW Breast Cancer, Breakthrough Award Level 3?

Closed September 30, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $12.6 million in total across about 2 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.